Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | ULK1 | O75385 | 3/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | BMX | P51813 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337276 | 1.00 | LRRK2 (0.41) | LRRK2TBK1JAK2ULK1ULK2 | |
| SCHEMBL15337706 | 1.00 | LRRK2 (0.41) | LRRK2TBK1JAK2ULK1ULK2 | |
| SCHEMBL19527712 | 1.00 | LRRK2 (0.41) | LRRK2TBK1JAK2ULK1ULK2 | |
| SCHEMBL15337510 | 0.90 | ULK1 (0.41) | LRRK2ULK1ULK2EGFRBMX | |
| SCHEMBL15337703 | 0.90 | ULK1 (0.41) | LRRK2ULK1ULK2EGFRBMX | |
| SCHEMBL15337482 | 0.87 | ULK1 (0.40) | TBK1ULK1ULK2EGFRBCL6 | |
| SCHEMBL19527806 | 0.87 | ULK1 (0.40) | TBK1ULK1ULK2EGFRBCL6 | |
| SCHEMBL15337710 | 0.87 | ULK1 (0.40) | TBK1ULK1ULK2EGFRBCL6 | |
| SCHEMBL15337651 | 0.87 | ULK1 (0.40) | TBK1ULK1ULK2EGFRBCL6 | |
| SCHEMBL15337495 | 0.83 | ULK1 (0.42) | ULK1ULK2EGFRBCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | LRRK2 391/4885TBK1 130/4885JAK2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.